CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Mar 10, 2025--
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( [email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-cmrx/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
1100 Poydras St., Suite 960
New Orleans, LA 70163
Lewis S. Kahn
855-768-1857
SOURCE: Kahn Swick & Foti, LLC
Copyright Business Wire 2025.
PUB: 03/10/2025 10:33 PM/DISC: 03/10/2025 10:33 PM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abacus Global Management, Inc. ('Abacus' or 'the Company') (NASDAQ: ABL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: 'Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue by Systematically Underestimating When People Will Die.' According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have 'red flags' in their past. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
a day ago
- Yahoo
IREN (NasdaqGS:IREN) Surges 48% in One Month After Strong Q3 Earnings
IREN recently reported strong third-quarter financial results, with a marked increase in sales and net income compared to the previous year, which stands out as a potential influence on the company's impressive 48% share price rise over the past month. While this growth in earnings is notable, the overall market environment also played a role, with a 1.8% market rise over the last seven days and a 13% increase over the past 12 months. Although IREN's nine-month results reveal ongoing challenges, recent positive earnings may have bolstered investor confidence, adding weight to the broader market's upward trend. We've spotted 3 weaknesses for IREN you should be aware of, and 2 of them are a bit concerning. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent strong quarterly earnings announcement for IREN (NasdaqGS:IREN) underscores the company's efforts to reshape its business strategy amid changing market conditions. The shift from primarily focusing on volatile cryptocurrency mining to expanding AI and cloud infrastructure could potentially stabilize earnings and boost margins over the long term. This business transformation is echoed in the robust total shareholder return of 102.28% over the past three years, showcasing a significant appreciation in shareholder value. Despite this impressive growth, IREN's shares have underperformed the US Software industry, which saw a 22.6% increase over the last year, highlighting the challenges inherent in its core operations. As IREN pivots towards new growth catalysts like the Childress and Sweetwater projects, the potential for revenue growth remains strong, driven by global demand for digital infrastructure. Analysts forecast a revenue growth of 52.0% annually over the next three years, suggesting promising prospects for near-future profitability transformation. It is essential to consider the recent share price increase in relation to the consensus analyst price target of US$18.52, which exceeds the current price of US$8.89 by 52.0%. This differential indicates a substantial potential for upward revaluation if IREN achieves forecasted growth targets. However, the company's reliance on crypto mining and its ambitious expansion introduce unavoidable risks that could impact these valuations. As always, investors should weigh both the opportunities and uncertainties when considering the company's future trajectory. Our comprehensive valuation report raises the possibility that IREN is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:IREN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
